@article{TCR8869,
author = {Aziz Zaanan and Simon Pernot and Julien Taieb},
title = {Treatment improvement by addition of leucovorin to S-1 plus oxaliplatin in patients with advanced gastric cancer},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 2},
year = {2016},
keywords = {},
abstract = {Regional differences in gastric cancer are observed between Asian and Western countries concerning prevalence, clinicopathologic features, as well as treatment strategies. Cisplatin and fluoropyrimidine based therapies are used as backbone of first-line chemotherapy for advanced gastric cancer treatment, although there is preference for 5-fluorouracil (5FU) or capecitabine in the West while S-1 is mostly used in Asia. REAL-2 and Al-Batran et al. studies have shown that oxaliplatin was as effective as cisplatin in combination with capecitabine or 5FU in Western countries (1,2). In the same way, in Asian countries, Yamada et al. have demonstrated recently that oxaliplatin could replace cisplatin in combination with S-1 for gastric cancer in first-line treatment with favorable safety profile (3). A third agent (docetaxel or epirubicin) may be added (more commonly in Western countries) for patients with good performance status (1,4).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/8869}
}